Search by Drug Name or NDC
NDC 72960-0112-02 DAXXIFY 100 U/1.2mL Details
DAXXIFY 100 U/1.2mL
DAXXIFY is a INTRAMUSCULAR INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Revance Therapeutics, Inc.. The primary component is BOTULINUM TOXIN TYPE A.
Product Information
| NDC | 72960-0112 |
|---|---|
| Product ID | 72960-112_4d7afe1d-492b-4ade-8d79-272f9d578883 |
| Associated GPIs | |
| GCN Sequence Number | 083814 |
| GCN Sequence Number Description | daxibotulinumtoxinA-lanm VIAL 100 UNIT INTRAMUSC |
| HIC3 | S7A |
| HIC3 Description | NEUROMUSCULAR BLOCKING AGENTS |
| GCN | 52876 |
| HICL Sequence Number | 048287 |
| HICL Sequence Number Description | DAXIBOTULINUMTOXINA-LANM |
| Brand/Generic | Brand |
| Proprietary Name | DAXXIFY |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | botulinum toxin type A |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | U/1.2mL |
| Substance Name | BOTULINUM TOXIN TYPE A |
| Labeler Name | Revance Therapeutics, Inc. |
| Pharmaceutical Class | Acetylcholine Release Inhibitor [EPC], Acetylcholine Release Inhibitors [MoA], Neuromuscular Blockade [PE], Neuromuscular Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761127 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72960-0112-02 (72960011202)
| NDC Package Code | 72960-112-02 |
|---|---|
| Billing NDC | 72960011202 |
| Package | 1 VIAL, SINGLE-USE in 1 CARTON (72960-112-02) / 1.2 mL in 1 VIAL, SINGLE-USE |
| Marketing Start Date | 2022-09-20 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |